title: Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.
abstract: We designed a phase II study evaluating the upfront combination of clofarabine and daunorubicin in acute myeloid leukemia (AML) patients≥60 years old. The median age of the 21 patients was 69 (range 60-85) years. Fourteen patients (67%) had unfavorable risk features. The principal toxicities were grade ≥3 infections and prolonged myelosuppression. Three (14%) deaths occurred from infectious complications. Six (28.6%) patients achieved complete remission including three (21.4%) of 14 patients with unfavorable AML. The median disease-free survival was 6.8 months and the median overall survival was 11.2 months.
authors.affiliation: Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States.
authors.forename: Carlos E
authors.initials: CE
authors.lastname: Vigil
authors.forename: Wei
authors.initials: W
authors.lastname: Tan
authors.forename: George
authors.initials: G
authors.lastname: Deeb
authors.forename: Sheila N
authors.initials: SN
authors.lastname: Sait
authors.forename: Annemarie W
authors.initials: AW
authors.lastname: Block
authors.forename: Petr
authors.initials: P
authors.lastname: Starostik
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Griffiths
authors.forename: James E
authors.initials: JE
authors.lastname: Thompson
authors.forename: Jessica D
authors.initials: JD
authors.lastname: Greene
authors.forename: Laurie A
authors.initials: LA
authors.lastname: Ford
authors.forename: Eunice S
authors.initials: ES
authors.lastname: Wang
authors.forename: Meir
authors.initials: M
authors.lastname: Wetzler
mesh_terms: D000227:Adenine Nucleotides / Q000008:administration & dosage; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000008:administration & dosage; D000077866:Clofarabine; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D000227:Adenine Nucleotides; D001087:Arabinonucleosides; D000077866:Clofarabine; D003630:Daunorubicin
keywords: AML; Clinical trial; Clofarabine; Daunorubicin; Elderly